[Multidisciplinar approach to the management of gliomas].
Gliomas represent two thirds of all primary brain tumors. Their prognosis depends directly upon their level of differentiation. On MRI, tumoral aggressivity is highlighted by contrast uptake and the infiltrative nature of the lesion. Clinical suspicion must however be confirmed by histology and molecular markers become essential to refine the diagnosis and tailor the treatment. Isocytrate dehydrogenase (IDH) mutations, codeletion of 1p and 19q and the presence of methylation of the MGMT promoter identify a subgroup of gliomas with better prognosis and may help predict response to treatment. Management of patients with primary brain tumors should always be defined in multidisciplinar tumor boards involving neurosurgeons, oncologists, radiation oncologists, neuropathologists and neuroradiologists.
Bianca
B
Moura
Denis
D
Migliorini
Jean
J
Bourhis
Roy
R
Daniel
Marc
M
Levivier
Andreas F
AF
Hottinger
D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D005910:Glioma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009154:Mutation; D010348:Patient Care Team / Q000458:organization & administration*; D011379:Prognosis; D011401:Promoter Regions, Genetic